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Abstract
Background: The Tingathe program utilizes community health workers to improve prevention of mother-to-child
transmission (PMTCT) service delivery. We evaluated the impact of antiretroviral (ARV) regimen and maternal CD4+ count on
HIV transmission within the Tingathe program in Lilongwe, Malawi.
Methods: We reviewed clinical records of 1088 mother-infant pairs enrolled from March 2009 to March 2011 who
completed follow-up to first DNA PCR. Eligibility for antiretroviral treatment (ART) was determined by CD4+ cell count
(CD4+) for women not yet on ART. ART-eligible women initiated stavudine-lamivudine-nevirapine. Early ART was defined as
ART for $14 weeks prior to delivery. For women ineligible for ART, optimal ARV prophylaxis was maternal AZT $6
weeks+sdNVP, and infant sdNVP+AZT for 1 week. HIV transmission rates were determined for ARV regimens, and factors
associated with vertical transmission were identified using bivariate logistic regression.
Results: Transmission rate at first PCR was 4.1%. Pairs receiving suboptimal ARV prophylaxis were more likely to transmit HIV
(10.3%, 95% CI, 5.5–18.1%). ART was associated with reduced transmission (1.4%, 95% CI, 0.6–3.0%), with early ART
associated with decreased transmission (no transmission), compared to all other treatment groups (p = 0.001). No
association was detected between transmission and CD4+ categories (p = 0.337), trimester of pregnancy at enrollment
(p = 0.100), or maternal age (p = 0.164).
Conclusion: Low rates of MTCT of HIV are possible in resource-constrained settings under routine programmatic conditions.
No transmissions were observed among women on ART for more than 14 weeks prior to delivery.
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Background
Effective medical interventions for prevention of mother-to-
child transmission of HIV (PMTCT) have been known since the
early 1990s, and in developed countries, new pediatric HIV
infections have become increasingly rare [1,2]. Globally, in
resource-limited settings, studies have demonstrated the efficacy
or effectiveness of various PMTCT interventions, including single-
dose nevirapine (sdNVP), combination prophylaxis, maternal
antiretroviral treatment (ART), and extended infant prophylaxis
[3–6]. These studies have informed the development of World
Health Organization (WHO) guidelines with simple and effective
interventions that can result in transmission rates of less than 5%
feasible, even in breastfeeding populations [7,8].
Despite these advances, an estimated 330,000 new infections
occur in children every year, the vast majority attributed to
vertical transmission [9]. Persistent poor outcomes in developing
countries generally are described as a result of HIV-infected
mothers and exposed infants not receiving medical services
[10,11]. However, outside the unique environment of controlled
research studies, few reports [12–14] have documented the real-
world effectiveness of PMTCT interventions when properly
administered within routine programmatic settings.
In partnership with the Malawi Ministry of Health, the Baylor
College of Medicine Tingathe Program (meaning ‘‘yes we can’’ in
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the local Chichewa language) utilizes community health workers
(CHWs) to improve uptake and delivery of routine, available
PMTCT interventions [14]. Tingathe CHWs support women to
engage in longitudinal care throughout the full PMTCT cascade,
starting with diagnosis of the woman at antenatal care (ANC) and
ending with final diagnosis of the infant. This report documents
transmission outcomes at first PCR for mother-infants pairs
enrolled in the Tingathe PMTCT program in Lilongwe, Malawi.
Methods
Ethics Statement
This retrospective study of routinely collected programmatic
data was performed in full accordance with the guidelines for
research outlined by the National Health Sciences Research
Committee of Malawi and the Baylor College of Medicine
institutional review board. All data collected were part of the
delivery of routine program services. For this study, both the
Malawi and Baylor review boards waived the need for written
consent. Verbal consent for HIV testing was obtained by
nationally certified HIV counselors in accordance with Malawi
National HIV Counseling and Testing guidelines. Data were de-
identified prior to analysis.
Study Design
We conducted a retrospective cohort analysis of mother-infant
pairs enrolled in the Tingathe program, March 2009 to March
2011, who had a first DNA PCR result available by January 28,
2012. Our primary outcome was infant HIV infection at first DNA
PCR. PCR was routinely performed at the first postnatal visit, as
early as 6 weeks of age.
Intervention Setting and Patient Population
The Tingathe PMTCT pilot program took place in Area 25 and
Kawale, two large peri-urban communities in Lilongwe, Malawi.
The estimated population is 310,000 people, with 15,000
deliveries per year, 2000 HIV-exposed infants delivered per year,
and adult HIV prevalence of 12% [15]. Over 96% of pregnant
women attend at least one antenatal visit [16], and 99% of
antenatal clinic (ANC) attendees were tested for HIV [11,17]. HIV
testing at antenatal care was performed via opt-out testing as per
Malawi Ministry of Health HIV guidelines [18].
The Tingathe Program
The Tingathe PMTCT program has been described in detail
elsewhere [14]. In brief, one Tingathe community health worker
(CHW) is assigned to each HIV-infected pregnant woman upon
diagnosis or enrollment into antenatal care (ANC). The CHW
supports the woman to engage in longitudinal care throughout the
full PMTCT cascade, starting with her diagnosis at ANC, and
including CD4+ cell count (CD4+), delivery of CD4+ results,
enrollment into ART clinic and initiation of ART if eligible,
delivery of antiretroviral (ARV) prophylaxis to mother and infants,
and DNA PCR testing of the infant. CHWs follow their clients at
their homes and health centers, from initial diagnosis until
confirmation of definitive HIV-uninfected status after cessation
of breastfeeding or successful ART initiation for HIV-infected
infants. Receipt of ARV regimen is recorded only upon
confirmation with the mother after delivery to verify that
medication has actually been ingested, not just dispensed [19].
HIV-infected women identified at labor and delivery or after the
birth of the infant are also followed and provided services but were
not included in this analysis.
Routine PMTCT Services and ARV Regimens Available at
Intervention Sites
All PMTCT clinical care was provided in accordance with
Malawi Ministry of Health and WHO guidelines [7,18]. In brief,
all women not already on ART at the time of enrollment had a
venipuncture performed to obtain blood for CD4+ cell count. If a
woman met ART eligibility criterion determined by CD4+, she
received the fixed-dose combination ART regimen of stavudine
(d4T)+lamivudine (3TC)+nevirapine (NVP). In August 2009,
CD4+ criterion for ART eligibility in HIV-infected pregnant
women in Malawi changed from CD4+#250 cells/mm3 to CD4+
#350 cells/mm [3,20]. Those women who did not meet eligibility
criterion received combination ARV prophylaxis with zidovudine
(AZT) at 28 weeks, sdNVP at the onset of labor, and a 7-day
AZT/3TC tail. Infants received sdNVP and AZT for 1 week
postnatally if their mothers received AZT for greater than 4 weeks
prior to delivery, and for 4 weeks postnatally if their mothers
received AZT for less than the minimum 4 weeks prior to delivery.
ARV Regimens
Figure 1 details the ARV regimens used for this study. Optimal
ARV prophylaxis was defined as the mother-infant pair receiving
complete ARV prophylaxis (including AZT, sdNVP) at the correct
time with the correct doses. Suboptimal ARV prophylaxis
included mother-infants who received no prophylaxis or sdNVP
only or AZT only. Due to the low numbers in each group, all these
suboptimal interventions were grouped together. Therefore, the
suboptimal ARV prophylaxis group included all mother-infant
pairs for which any component of the optimal ARV prophylaxis
regimen was either omitted or given incorrectly. Mother-infant
pairs in which the women missed only the post-delivery AZT/
3TC tail were included in the optimal ARV prophylaxis group, as
the tail is provided to prevent resistance in the mother and is not
thought to influence transmission [20,21]. All women who
received ART for their own health were grouped in the ART
group, with those who initiated ART at least 14 weeks prior to
delivery further categorized as early ART.
Infant HIV Testing
In accordance with national guidelines, infants received their
first HIV test by DNA PCR by Dried Blood Spot (DBS) at or after
6 weeks of life [18]. Transmission was defined as positive PCR
result at first DNA PCR.
Statistical Analysis
Electronic clinical records of all HIV-infected pregnant women
enrolled March 2009 -March 2011 were reviewed. Data were de-
identified prior to analysis. Aggregate data were reported as mean
with standard deviation (SD) or median with interquartile range
(IQR) based on normality. We computed HIV transmission rates
as proportions with 95% confidence intervals (CI), using the
modified Wald method. Proportions were compared initially with
a univariate global Pearson chi-square test. When global testing
indicated a significant difference somewhere within the data,
bivariate pair-wise, post hoc comparisons were made using either
chi-square or Fisher exact tests, with alpha adjusted for multiple
comparisons using Bonferroni’s correction. Only pair-wise com-
parisons with the p-value less than adjusted alpha were considered
significant. Continuous variables were compared between two
groups using an independent-samples t test. All statistical analyses
were performed using IBM SPSS Statistics (version 20.0.0, IBM
Corporation, Armonk, NY).
Low Rates of MTCT in a Routine Program in Malawi
PLOS ONE | www.plosone.org 2 May 2013 | Volume 8 | Issue 5 | e64979
Results
From March 2009 to March 2011, 1687 HIV-infected pregnant
women were enrolled into the Tingathe PMTCT program. Figure 2
details the outcomes for these women and their exposed infants
through the first infant DNA PCR. There were 97 maternal-fetal-
infant deaths as well as 253 who moved from the catchment area,
were lost or refused ongoing care prior to infant birth. Of 1337
recorded live births, there were 39 maternal-infant deaths as well
as 210 who either moved, were lost, or refused ongoing care.
Therefore, there were 1088 (81.4%) with a first PCR result
recorded.
Baseline Characteristics
Table 1 describes baseline characteristics of women in our
cohort. Of the 1088 mother-infant pairs with first PCR result
recorded, the mean age of the woman was 27.8 years (SD=5.2).
Median gestational age at program entry was 24 weeks (IQR 20–
28), and 699 (64.2%) were in their first or second trimesters. The
majority of women (71.7%) were newly diagnosed with HIV
infection at program entry. Of those newly diagnosed, 307 (28.2%)
were eligible for ART. Of the 307 women eligible for ART, 192
(62.5%) were eligible using the threshold of#250 CD4+ cell/mm3
and 115 (37.5%) were eligible using the #350 cell/mm3 threshold.
There were 262 (24.1%) women already on ART at program
entry. Most women (65.1%) had not disclosed their HIV status to
their partners. Average baseline CD4+ cell count was 414 cells/
mm3 (SD=227) for the 803 women not on ART at the time of
entry into the program and for whom CD4+ was available.
Compared to women whose infants received a first PCR, those
who were lost to follow-up (lost, moved, and refused to participate)
were younger (mean maternal age 26.9 [SD 5.8] versus 27.8 [SD
5.2] years, p = 0.002), greater proportion enrolled during the first
trimester of pregnancy [9% vs. 5% in 1st Trimester; p = 0.001];
greater proportion newly diagnosed with HIV at enrollment
[84.8% vs. 71.7%; p,0.001]; greater proportion on ART at
enrollment [24.6% vs. 13.2%; p,0.001]; and greater proportion
with partners who were not aware of the mother’s HIV status
[29.3% vs. 17.2%; p,0.001]. There were no differences noted in
baseline CD4 cell count.
Among the 1088 infants, median age at first PCR was 1.7 (IQR
1.5–2.5) months: 96.6% were tested at,6 months of age and 81%
were tested at # 12 weeks of age.
Figure 1. Description and explanations of antiretroviral regimens used for analysis. *sdNVP: single dose of nevirapine for the mother
taken at the onset of labor and a single dose of nevirapine for the infant administered within 72 hours of delivery. **Due to low patient numbers in
each individual grouping, these suboptimal interventions were grouped together. ***Based on 2006 WHO PMTCT guidelines. Abbreviations: ARV
(antiretroviral), ART (antiretroviral therapy), AZT (zidovudine).
doi:10.1371/journal.pone.0064979.g001
Figure 2. Outcomes for HIV-infected pregnant women and HIV-
exposed infants enrolled in the Tingathe program. *After the
maternal deaths, all five infants were transferred to the care of another
caregiver and moved out of the program catchment area.
doi:10.1371/journal.pone.0064979.g002
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HIV Transmission and ARV Regimens
Of the 882 (81.1%) performed at # 12 weeks, 38 (4.3%) were
positive; of the 104 (9.6%) performed at .12–16 weeks, 3 (2.9%)
were positive; of the 65 (6%) performed at.16–24 weeks, 3 (4.6%)
were positive; of the remaining 37 (3.4%) performed, 1 (2.7%) was
positive. There was no difference between the transmission rates of
those with first PCR performed at # 12 weeks of age versus those
.12 weeks of age (4.3% versus 3.4%; p= 0.555).
Among the 485 women who received ART, 187 (38.6%)
received ART late (ART ,14 weeks prior to delivery). Median
duration of antenatal ART was 19 (IQR 8.9–104.9) weeks for the
ART group as a whole, 82 (IQR 22–159) weeks for the early ART
group, and 7.1 (IQR 4.4–9.9) weeks for the late ART group. Of
the women who received early ART 194/298 (65%) were on ART
at least 40 weeks prior to infant birth.
Figure 3 illustrates ARV regimen by trimester. Of those women
who presented in the 1st trimester, 85% received either early ART
(50%) or optimal prophylaxis (35%). Of those who presented in
the 2nd trimester, 73% received either early ART (29%) or optimal
prophylaxis (44%). Finally, of those women who presented in the
3rd trimester, 73% received either early ART (20%) or optimal
prophylaxis (53%).
Table 2 documents how HIV transmission rates varied
according to ARV regimen received by the mother-infant pair.
Those who received suboptimal ARV prophylaxis had the highest
rate of transmission (10.3%, 95% CI, 5.5–18.1%). Those who
received ART had reduced transmission (1.4%, 95% CI, 0.6–
3.0%), whereas early ART (initiated ART $14weeks prior to
delivery) was associated with the lowest transmission, with no
transmissions among these 298 women (p,0.001 compared to all
other ARV regimens; Table 2).
Factors Associated with HIV Transmission
Factors significantly associated with HIV transmission on
bivariate analysis included ART eligibility, type of ARV regimen,
and the duration of antenatal ART (Table 3). Specifically, women
already receiving ART at the time of enrollment or women
initiated on ART early in the course of the pregnancy were less
likely to transmit HIV. Receiving ART for at least 14 weeks
antenatally (early ART) was associated with decreased transmis-
sion (no transmission) compared to all other forms of ARV
prophylaxis (p = 0.001), whereas receiving ART for less than 14
weeks (late ART) was associated with increased transmission of
HIV (p = 0.001).
HIV Transmission by Baseline CD4+ Cell Count
CD4+ counts were only obtained on women not on ART at the
time of program initiation. Of these 826 women, 803 (97.2%) had
Table 1. Characteristics of 1088 HIV positive pregnant women at enrollment in the Tingathe program.
Characteristic Result
Age, mean years (SD) 27.8 (5.2)




Missing data 5 (0.4)
HIV status at enrollment, n (%)
Newly diagnosed as HIV-infected 780 (71.7)
Already known to be HIV-infected 308 (28.3)
ART eligibility at enrollment
On ART 262 (24.1)
Eligible but not on ART 307 (28.2)
Not Eligible 496 (45.6)
Missing data 23 (2.1)
CD4+ cells/mm3 at PMTCT entry for women not already on ART, n/N (%)a




Missing data 23 (2.1)
Partner Disclosure status at enrollment, n (%)b
Partner involved and disclosed 319 (29.3)
Partner involved, not disclosed 708 (65.1)
Partner not involved 61 (5.6)
aOf the 1088 mother-infant pairs with first DNA PCR results, 262 mothers were already on ART, 23 with no corresponding maternal CD4 results, therefore 803 available
CD4 results with corresponding PCR results.
bPartner disclosed defined as partner having knowledge of maternal HIV status. Partner non-involved defined as a partner who has died, or is otherwise separated from
the mother.
Abbreviations: ART (antiretroviral therapy), CD4+ (CD4+ cell count), PMTCT (prevention of mother-to-child transmission).
doi:10.1371/journal.pone.0064979.t001
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CD4+ counts recorded at the time of program registration. No
difference in vertical transmission rate was detected according to
CD4+ level at enrollment (p = 0.302).
Maternalage,gestational trimester,HIVstatusandCD4+countat
the time of enrollment, partner disclosure, delivery location, and
breast-feeding statuswerealsonot associatedwithHIV transmission.
(Table 3).
Recommended ARV Regimen not Received
Of the 1088 mother-infant pairs, 96 (8.8%) received suboptimal
ARVprophylaxis.Evenamongthe507womenwhoreceivedoptimal
combination ARV prophylaxis, 34 (6.7%) did not receive the
recommended one-week AZT/3TC tail. Therefore, 130 (12%) did
not receive the recommendedregimen.Furthermore, 31of307ART
eligible women did not initiate ART even after infant delivery.
Figure 3. Antiretroviral regimen by trimester at enrollment. aFor explanations of ARV regimen categories please refer to Figure 1.
Abbreviations: ART (antiretroviral therapy), ARV (antiretroviral).
doi:10.1371/journal.pone.0064979.g003









ARV regimen categorya, n (%) ,0.001
Prophylaxis 38 (84.4) 565 (54.2) 6.3 (4.6–8.6)
Antiretroviral therapy 7 (15.6) 478 45.8) 1.4 (0.6–3.0)
ARV regimen categorya, n (%) ,0.001
Suboptimal ARV prophylaxis 10 (22.2) 86 (8.3) 10.3 (5.5–18.1) 0.001c
Optimal combination ARV prophylaxis 28 (62.2) 479 (45.9) 5.5 (3.8–7.9) 0.032
Late ART (initiated ,14 weeks prior to delivery) 7 (15.6) 180 (17.3) 3.7 (1.7–7.7) 0.767
Early ART (initiated $14 weeks prior to delivery) 0 (0.0) 298 (28.5) 0.0 (0.0–1.5) 0.001c
aFor explanations of ARV regimen categories please refer to Figure 1.
bEarly vertical transmission rate calculation: number positive first PCR results/number of total first PCR results.
cDenotes p, alpha, adjusted to 0.0125 to account for multiple comparisons. Post hoc analysis performed only if the global p-value (in bold) was ,0.05. (see Methods).
Abbreviations: PCR (polymerase chain reaction)- DNA PCR test for HIV, ART (antiretroviral therapy),
doi:10.1371/journal.pone.0064979.t002
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Table 3. Characteristics of women and infants associated with positive first PCR versus negative first PCR.
Characteristic
Infants with first PCR positive
(N=45)
Infants with first PCR negative
(N=1043) p-value
Maternal Age, mean years (SD) 26.7 (4.9) 27.9 (5.3) 0.164
Trimester of pregnancy: n/N (%) 0.100
First 5/45 (11.1) 49/1038 (4.7)
Second 28/45 (62.2) 617/1038 (59.4)
Third 12/45 (26.7) 372/1038 (35.8)
HIV status at enrollment, n/N (%) 0.355
Newly diagnosed as HIV-infected 35/45 (77.8) 745/1043 (71.4)
Already known to be HIV-infected 10/45 (22.2) 298/1043 (28.6)
ART eligibility at enrolment, n/N (%) 0.015
On ART 2/39 (5.1) 260/1026 (25.3) 0.002a
Eligible but not on ART 15/39 (38.5) 292/1026 (28.5) 0.176
Not Eligible 22/39 (56.4) 474/1026 (46.2) 0.210
CD4+ cells/mm3 at PMTCT entry for women not already
on ART, n/N (%)b
0.337
# 250 8/37 (21.6) 184/766 (24.0)
251–349 10/37 (27.0) 139/766 (18.1)
350–499 12/37 (32.4) 212/766 (27.7)
$500 7/37 (18.9) 231/766 (30.2)
ARV regimen category, n/N (%)c ,0.001
Prophylaxis 38 (84.4) 565 (54.2)
Antiretroviral therapy 7 (15.6) 478 45.8)
ARV regimen category, n/N (%)c ,0.001
Suboptimal ARV prophylaxis 10/45 (22.2) 86/1043 (8.2) 0.001a
Optimal comb. ARV prophylaxis 28/45 (62.2) 479/1043 (45.9) 0.032
Antiretroviral therapy 7/45 (15.6) 478/1043 (45.8) ,0.001a
Duration of antenatal ART, n/N (%) 0.001a
Late ART (initiated ,14 weeks prior to delivery) 7/7 (100.0) 180/478 (37.7)
Early ART (initiated $14 weeks prior to delivery) 0/7 (0.0) 298/478 (62.3)
Partner Disclosure status at enrollment, n/N (%)d 0.235
Partner involved and disclosed 13/45 (28.9) 306/1043 (29.3)
Partner involved, not disclosed 32/45 (71.1) 676/1043 (64.8)
Partner not involved 0/45 (0.0) 61/1043 (5.8)
Delivery Location, n/N (%) 0.293
Home 2/45 (4.4) 24/1043 (2.3)
Health center 43/45 (95.6) 1017/1043 (97.5)
Traditional Birth Attendant 0/0 (0.0) 2/1043 (0.2)
Feeding Choice, n/N (%) 0.708
Breast feeding 44/44 (100.0) 1020/1036 (98.5)
Mixed 0/44 (0.0) 1/1036 (0.1)
Replacement feeding 0/44 (0.0) 15/1036 (1.4)
aDenotes p, alpha, equal to 0.05 for 2-category comparisons or adjusted to 0.017 for 3-category comparisons. Post hoc analysis performed only if the global p-value (in
bold) was ,0.05. (see Methods).
b1088 available PCR results, of these 262 mothers were already on ART, 23 with no corresponding maternal CD4 results, therefore 803 available CD4 results with
corresponding PCR results.
cFor explanations of ARV regimen categories please refer to Figure 1.
dPartner disclosed defined as partner having knowledge of maternal HIV status. Partner non-involved defined as a partner who has died, or is otherwise separated from
the mother.
Abbreviations: PCR (polymerase chain reaction)- DNA PCR test for HIV, ART (antiretroviral therapy), ARV (antiretroviral), CD4+ (CD4+ cell count), PMTCT (prevention of
mother-to-child transmission).
doi:10.1371/journal.pone.0064979.t003
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Discussion
Results from our cohort of HIV-infected women and their
exposed infants suggest that low rates of vertical transmission of
HIV are possible in resource-constrained settings. We observed an
overall transmission rate at first DNA PCR of 4.1%. These results
compare favorably with other reports from resource-constrained
settings, including studies limited to women on ART [13,22,23]
and PMTCT clinical trials [5,6,20].
Study results have been mixed regarding the relationship
between immunosuppression and vertical transmission
[1,2,13,24,25]. In the context of appropriate PMTCT delivery
that includes ART for eligible women, our results suggest that
CD4+ cell count at the time of entry into PMTCT does not
significantly impact transmission. In our cohort, those women at
highest risk of transmitting the virus due to severe immunosup-
pression (,250 cells/mm3) had transmission rates that were not
significantly different from those with less immunosuppression.
As expected, ART was more protective than was any other
ARV regimen. Furthermore, starting ART at least 14 weeks prior
to delivery (early ART) yielded the most benefit in reducing
transmission, with no transmissions noted in the early ART group.
These results are consistent with findings that complete viral
suppression usually takes place after 12 to 16 weeks of therapy
[24,26,27]. Other clinical studies have reported similar results,
including a study from Zambia that found that women who
received ART for 4 or fewer weeks had a 5.5- fold increased odds
of transmission when compared with women on HAART for at
least 13 weeks [22]. Similarly, all women enrolled in the Dream
Program in Malawi, Tanzania, and Mozambique were started on
ART at 25 weeks and were found to have a transmission rate of
just 0.8–1.2% at 1 month [23]. Importantly, over one third of the
women in our cohort who were on ART received it for fewer than
14 weeks prior to delivery (i.e., less than the optimal longer
duration). Moreover, over one-third of our cohort was enrolled
during the third trimester. Therefore, our results not only confirm
that early initiation of ART yields maximal benefits in reducing
transmission but also highlight that increasing efforts need to be
made to ensure that women present to antenatal care sooner and
early initiation of ART be a priority PMTCT intervention.
Although the patients in this cohort were all treated under the
2006 WHO guidelines [7], there are some implications for policy
makers as they implement the 2010 WHO guidelines (Table 4)
[28]. There is similar complexity and steps between the
combination prophylaxis of 2006 and both option A and option
B from 2010. Most important, as with the WHO 2006 guidelines,
the WHO 2010 guidelines still require measurement of CD4+ to
determine which regimen to administer for option A and to
determine whether ART should be stopped after breastfeeding for
option B. This complexity can lead to errors made by both the
healthcare system and patients. In our program, even with CHW
case management, 12% of patients did not receive the complete
recommended regimens. In settings where CHW case manage-
ment is not present, the risk of errors is likely to be even higher. It
appears that the multiple steps necessary for options A and B may
be challenging for patients to negotiate.
The Malawi Ministry of Health recently embarked on a novel
PMTCT strategy called option B+ (Table 4) that starts all HIV-
infected pregnant women on triple ARV prophylaxis regardless of
eligibility for ART and, therefore, requires no CD4+ testing
[29,30]. Our results support this approach for several reasons.
First, given the high rate of errors with combination prophylaxis
and ART threshold initiation in our cohort, option B+ may
provide a simpler alternative because all HIV-infected pregnant
women will be receiving the same triple ARV for life without the
need to first assess CD4+ cell counts. Second, the multiple
challenges to accessing reliable CD4+ testing in resource-
constrained settings renders a system that obviates the need for
CD4+ testing a favorable option. Finally, ART at the time of
conception appears to be associated with improved outcomes and
reduced transmission. Within our cohort, the majority of women
receiving early ART were initiated on ART earlier than 40 weeks
prior to delivery, indicating that they were receiving treatment at
the time of conception. Results from cohorts in South Africa, the
UK and Ireland, and France all suggest that women who become
pregnant on ART have lower transmission rates as compared to
women who initiate therapy after becoming pregnant (0.7% vs.
5.7%, p= 0.01; 0.1% vs. 1.3%, p= 0.001; and 16% vs. 45%,
p= 0.17, respectively) [13,31,32]. Our results support the findings
in these studies and provide support for lifelong ART to reduce
future transmissions, as well as highlight the need to test women
prior to becoming pregnant.
However, an important note is that option B+ in Malawi uses an
efavirenz (EFV)-based ART regimen, as compared to the NVP
based treatment regimen used in our cohort. The potential risk of
rare EFV related teratogenicity in the first trimester [33] needs
ongoing monitoring, especially given the number of HIV-infected
women who may have repeat pregnancies while on EFV. This
potential risk also further highlights the need for family planning
services to be included and prioritized with roll out of option B+.
Despite support for early ART initiation and option B+, the
efficacy of this approach will be compromised unless efforts are
made to promptly link newly identified women to ART services
and to ensure identification, enrollment into care, and testing of
exposed infants. Significant challenges to early identification of
women and prompt ART initiation remain [34–36], and various
studies have begun to identify some of these obstacles [37], such as
economic concerns, stigma, obstruction from spouses or families,
and suboptimal provider-patient interactions. The barriers to
initiation of and adherence to ART [38] need to be investigated
further so that effective interventions can be developed. Finally,
there are early data from the routine monitoring systems in
Malawi demonstrating a dramatic increase in the number of
pregnant women initiating ART and retention at 6 and 12months
similar to non-pregnant adults on ART [30]. However, additional
studies to support these findings and further evaluate the impact of
option B+ on HIV transmission, long-term retention, and
outcomes are needed.
The most important limitation in our study was loss-to-follow-
up (LTFU). Not all HIV-infected women identified at our clinics
joined our program, and 14% of our enrolled cohort were lost or
refused ongoing care after enrollment. These results compare
favorably with other PMTCT programs, in which LTFU rates of
25–75% have been observed [12,13,18]. However, our transmis-
sion rates did not include those LTFU (lost, moved, refused care)
and it is very possible that outcomes were worse in this group.
Although we cannot confirm this, those LTFU likely did not
receive a complete course of ARVs. Furthermore, the results from
this study suggest that, compared to those with first PCR results
available, those women who were LTFU were more likely to be
younger in age and have newly diagnosed HIV; they were also less
likely to be on ART at enrollment, and to have partners who were
unaware of their HIV status. These characteristics may have also
contributed to worse outcomes including increased vertical HIV
transmission. CHW support of women to aid in the disclosure
process as well as the creation of improved opportunities for
antenatal couples testing might improve HIV disclosure to
partners, thus leading to decreased maternal loss to follow-up
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and overall decreased MTCT. Innovative solutions to address
reasons for LTFU and improve completion of the PMTCT
cascade are needed to eradicate vertical transmission.
There were other limitations to our study. Since we included all
first PCR test results and did not use a strict age range of 6–8
weeks, our findings are not directly comparable with other studies
that use this age cut off. In Malawi, infant feeding guidelines
recommend breastfeeding until children reach two years of age.
The vast majority of our cohort continues to breastfeed, therefore,
final infection status will be reported later.
These results provide reassurance that low HIV transmission
rates can be achieved even in resource-limited settings. Maximum
benefit is received from ART started at least 14 weeks prior to
delivery for eligible women versus other regimens. Furthermore,
more advanced HIV disease as indicated by lower baseline CD4+
cell count does not impact transmission among women in the
setting of appropriate provision of maternal ART and PMTCT
prophylaxis. Improving timely initiation of ART and PMTCT
prophylaxis is essential to effectively reduce MTCT of HIV on a
global scale.
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